Viveve Medical, Inc. (VIVE) Expected to Announce Quarterly Sales of $3.63 Million
Equities analysts forecast that Viveve Medical, Inc. (NASDAQ:VIVE) will announce sales of $3.63 million for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Viveve Medical’s earnings, with estimates ranging from $3.58 million to $3.71 million. Viveve Medical posted sales of $1.85 million during the same quarter last year, which would suggest a positive year over year growth rate of 96.2%. The firm is scheduled to announce its next quarterly earnings report on Thursday, November 9th.
On average, analysts expect that Viveve Medical will report full-year sales of $3.63 million for the current fiscal year, with estimates ranging from $14.78 million to $16.10 million. For the next financial year, analysts anticipate that the business will report sales of $24.90 million per share, with estimates ranging from $24.50 million to $25.16 million. Zacks’ sales averages are a mean average based on a survey of research analysts that that provide coverage for Viveve Medical.
Viveve Medical (NASDAQ:VIVE) last released its earnings results on Thursday, August 10th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.21. The firm had revenue of $3.08 million during the quarter, compared to analysts’ expectations of $3.24 million. Viveve Medical had a negative return on equity of 244.96% and a negative net margin of 266.93%. The business’s revenue was up 97.4% on a year-over-year basis. During the same period last year, the business earned ($0.66) earnings per share.
VIVE has been the subject of a number of research reports. Raymond James Financial, Inc. initiated coverage on Viveve Medical in a research note on Thursday, May 25th. They set an “outperform” rating and a $10.00 target price for the company. ValuEngine raised Viveve Medical from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Maxim Group reissued a “buy” rating and set a $11.00 target price on shares of Viveve Medical in a research note on Friday, August 11th. Cowen and Company reissued a “buy” rating and set a $11.00 target price on shares of Viveve Medical in a research note on Thursday, August 17th. Finally, B. Riley reissued a “buy” rating and set a $10.00 target price on shares of Viveve Medical in a research note on Wednesday, May 17th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $12.80.
Viveve Medical (NASDAQ:VIVE) opened at 5.43 on Friday. The stock has a 50 day moving average of $6.07 and a 200 day moving average of $6.52. Viveve Medical has a 52-week low of $3.75 and a 52-week high of $11.16. The stock’s market capitalization is $105.37 million.
In other Viveve Medical news, CFO Scott Durbin bought 5,000 shares of the stock in a transaction that occurred on Wednesday, August 23rd. The stock was acquired at an average cost of $5.25 per share, with a total value of $26,250.00. Following the purchase, the chief financial officer now owns 11,568 shares in the company, valued at $60,732. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 35.10% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. California State Teachers Retirement System acquired a new position in Viveve Medical during the 2nd quarter worth approximately $190,000. State Street Corp acquired a new position in Viveve Medical during the 2nd quarter worth approximately $1,282,000. Manatuck Hill Partners LLC boosted its position in Viveve Medical by 128.6% during the 2nd quarter. Manatuck Hill Partners LLC now owns 400,000 shares of the company’s stock worth $2,872,000 after acquiring an additional 225,000 shares during the last quarter. HighTower Advisors LLC boosted its position in Viveve Medical by 33.2% during the 2nd quarter. HighTower Advisors LLC now owns 1,723,751 shares of the company’s stock worth $12,379,000 after acquiring an additional 430,033 shares during the last quarter. Finally, Numeric Investors LLC acquired a new position in Viveve Medical during the 2nd quarter worth approximately $330,000. 65.80% of the stock is owned by institutional investors and hedge funds.
Viveve Medical Company Profile
Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.